FDA Inspection 1137071 — Progenics Pharmaceuticals, Inc.
The FDA completed an inspection of Progenics Pharmaceuticals, Inc. on Feb 26, 2021 in New York, NY. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection details
- Classification
- No Action Indicated (NAI)
- End Date
- Feb 26, 2021
- Fiscal Year
- 2021
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- New York, NY (United States)
Additional details
Postmarket Adverse Drug Experience (PADE)